Aptahem has set up a Scientific Advisory Board (SAB) which will act as clinical support for Aptahem’s development team and provide cardiovascular expertise. The members of the SAB have long and extensive experience of clinical work in the cardiovascular field.

Anders Bylock

CMO & Chairman of the Scientific Advisory Board

Associate Professor and licensed physician Bylock is a well-known expert in the field of cardiovascular development within pre-clinical and clinical studies as well as regulatory applications. Associate Professor Bylock specialised in thoracic surgery at Uppsala University Hospital and has since then had an international career in cardiovascular research and development in Europe and the USA. He began working in the pharmaceuticals industry as Director of Clinical Research at MSD Sweden, but over the past 17 years  has held several positions at AstraZeneca, such as Director for the Clinical Pharmacology and Clinical Drug Safety Departments. During the years 2011 – 2016, Dr. Bylock was Senior Global Director of the department of Global Clinical Development & Medical Affairs at Boehringer Ingelheim GmbH & Co KG in Germany, where he served as the medical director of a large number of cardiovascular projects in various stages.

Hans Peter Schwarz

A Physician by training, Professor Schwarz has acquired 30 years of global industry and research and development experience in Biotherapeutics with a focus on translational medicine in rare diseases. As the VP Research and Development at Baxter BioScience/Baxalta he was responsible for preclinical/clinical research and life cycle management of biologics, i.e. recombinant and plasma derived therapeutic proteins. Professor Schwarz has managed a global whole integrated R&D team located in Los Angeles and Vienna with a best in class preclinical organisation. He has global regulatory experience with leadership roles in FDA Advisory Committees. During his leadership, the BioScience’s R&D portfolio was successfully built and advanced leading to licensure and launch of key biologics in the areas Hemophilia, Thrombosis, Immunology, Neurology, and BioSurgery. Professor Schwarz’ scientific career has resulted in 75 approved patent applications, 360 scientific abstracts and more than 230 peer reviewed publications.

Mats Eriksson

Associate Professor and Chief Physician Mats Eriksson has many years of experience from the Anesthesia & Intensive Care Clinic, Academic Hospital, Uppsala. Associate Professor Eriksson has extensive scientific production, which includes more than 60 scientific original articles, published in internationally reputable journals, and more than 70 scientific papers, published as book chapters, review articles and congress presentations, including as multiple invited speaker. He has been a scientific supervisor of 5 PhD students as well as co-authors in another 5 dissertations. Research has largely focused on the coagulation effect in sepsis. Associate Professor Eriksson has been the national coordinator for an international clinical study. He was one of the participants in the Medical Committee’s Expert Committee, for the development of guidelines for treatment with anticoagulants in atrial fibrillation. Associate Professor Eriksson has over 7 years experience in work in the pharmaceutical industry, where positions include including International Medical Advisor and VP Research & Clinical Develop / Medical Director at Orexo AB.